Search - tctmd.com

Displaying 201 - 220 of 299

Sort: Relevancy | Date

Manuscript

Calcification and Thrombosis as Mediators of Bioprosthetic Valve Deterioration

February 06, 2019

News Daily News

FORWARD Registry: Low Mortality Rate Seen 1 Year After TAVR With Evolut R

Todd Neale

November 20, 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2018

Shelley Wood

October 31, 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2018

Shelley Wood

October 02, 2018

News Conference News TCT 2018

PORTICO I: Low 1-Year Mortality With Repositionable TAVR Valve in OUS Experience

L.A. McKeown

September 27, 2018

Presentation TCT 2018

Featured Case: Late Coronary Sinus Thrombosis After TAVR: An Unexpected and Deadly Event

Presenter: Jorge Cortes Lawrenz, Juan F. Granada, Oscar A. Mendiz, Carlos Cabrera Arroyo, Carlos D Calderas, Anibal A. Damonte, Nabeel Ismaeil

September 24, 2018

Presentation TCT 2018

Clinical Impact of Valve Thrombosis After TAVR

Presenter: Martina Kelly Speight

September 23, 2018

News Daily News TCT 2018

High Mortality but Durable Results With Valve-in-Valve TAVR

Michael O'Riordan

September 23, 2018

Presentation TCT 2018

Case #8: A Case of Asymptomatic Leaflet Thrombosis: Management Strategies

Presenter: Philippe Genereux, Josep Rodés-Cabau, Suzanne V. Arnold, Wayne B. Batchelor, Pablo Lamelas, Tullio Palmerini, Shigeru Saito, Tobias Tichelbäcker

September 23, 2018

Presentation TCT 2018

Case #4: Clinically Significant TAVR Leaflet Thrombosis

Presenter: Samir R. Kapadia, Bernard Prendergast, Eric Eeckhout, Ganesh Manoharan, John C. Messenger, Bernhard Reimers, Paul Sorajja, Eric Vang

September 23, 2018

Presentation TCT 2018

Should We Anticoagulate All Bioprosthetic Aortic Valves? Rationale, Ongoing Studies, and Recent Trends

Presenter: Michael J. Mack, Bernard Prendergast, George D. Dangas

September 22, 2018

Presentation TCT 2018

New Guidelines and Classification of Bioprosthetic Valve Dysfunction and Failure: Implications and Thoughts on TAVR Durability

Presenter: Michael J. Mack, Bernard Prendergast, Davide Capodanno

September 22, 2018

Presentation TCT 2018

The Spectrum of Leaflet Thrombosis in Bioprosthetic Aortic Valves - Prevalence, Clinical Consequences, and Practical Management Strategies

Presenter: Michael J. Mack, Bernard Prendergast, Lars Sondergaard

September 22, 2018

Presentation TCT 2018

To Split or Not to Split: The Role of BASILICA to Reduce the Risk of Coronary Obstruction During ViV (and other TAVR) Procedures

Presenter: Michael J. Mack, Bernard Prendergast, Adam B. Greenbaum

September 22, 2018

Presentation TCT 2018

To Crack or Not to Crack: The Role of Fracturing Bioprosthetic Valves During ViV Procedures

Presenter: Michael J. Mack, Bernard Prendergast, Adnan K. Chhatriwalla

September 22, 2018

Presentation TCT 2018

How to Screen for Risk of Coronary Obstruction Risk on CT Prior to Aortic Valve-in-Valve Procedures

Presenter: Michael J. Mack, Bernard Prendergast, Philipp Blanke

September 22, 2018

Presentation TCT 2018

Clinical Lessons from the Global Aortic VIVID Registry Optimizing Procedural Outcomes

Presenter: Michael J. Mack, Bernard Prendergast, John G. Webb

September 22, 2018

News Conference News TCT 2018

Novel LAA Closure Device Shows Promise in Early Experience

L.A. McKeown

September 22, 2018

News Conference News PCR London Valves 2018

Small Series Speak to Inching Progress in Off-Label or Expanded TAVR Applications

Shelley Wood

September 10, 2018

News Conference News ESC 2018

ESC 2018: Trimming DAPT, New NOAC Niches, Aspirin Scrutiny for Primary Prevention, and More

Shelley Wood

August 20, 2018

Advertisement

Calcification and Thrombosis as Mediators of Bioprosthetic Valve Deterioration

FORWARD Registry: Low Mortality Rate Seen 1 Year After TAVR With Evolut R

TCTMD’s Top 10 Most Popular Stories for October 2018

TCTMD’s Top 10 Most Popular Stories for September 2018

PORTICO I: Low 1-Year Mortality With Repositionable TAVR Valve in OUS Experience

Featured Case: Late Coronary Sinus Thrombosis After TAVR: An Unexpected and Deadly Event

Clinical Impact of Valve Thrombosis After TAVR

High Mortality but Durable Results With Valve-in-Valve TAVR

Case #8: A Case of Asymptomatic Leaflet Thrombosis: Management Strategies

Case #4: Clinically Significant TAVR Leaflet Thrombosis

Should We Anticoagulate All Bioprosthetic Aortic Valves? Rationale, Ongoing Studies, and Recent Trends

New Guidelines and Classification of Bioprosthetic Valve Dysfunction and Failure: Implications and Thoughts on TAVR Durability

The Spectrum of Leaflet Thrombosis in Bioprosthetic Aortic Valves - Prevalence, Clinical Consequences, and Practical Management Strategies

To Split or Not to Split: The Role of BASILICA to Reduce the Risk of Coronary Obstruction During ViV (and other TAVR) Procedures

To Crack or Not to Crack: The Role of Fracturing Bioprosthetic Valves During ViV Procedures

How to Screen for Risk of Coronary Obstruction Risk on CT Prior to Aortic Valve-in-Valve Procedures

Clinical Lessons from the Global Aortic VIVID Registry Optimizing Procedural Outcomes

Novel LAA Closure Device Shows Promise in Early Experience

Small Series Speak to Inching Progress in Off-Label or Expanded TAVR Applications

ESC 2018: Trimming DAPT, New NOAC Niches, Aspirin Scrutiny for Primary Prevention, and More

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content